Liver Cancer (Hepatocellular Carcinoma)
Liver Cancer (Hepatocellular Carcinoma)
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, arising from hepatocytes, the main functional cells of the liver. It is distinct from metastatic liver cancer, in which tumors spread to the liver from another organ. Globally, HCC is a major cause of cancer-related illness and death, in part because it often develops on a background of chronic liver disease and may not cause symptoms until it is advanced. Its burden is especially high in regions where chronic hepatitis B or hepatitis C infection is common, though rates have also increased in many countries alongside metabolic dysfunction–associated steatotic liver disease, obesity, and type 2 diabetes.
From a public health perspective, HCC is closely tied to long-term liver injury and cirrhosis. Common risk factors include chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, aflatoxin exposure in some parts of the world, inherited metabolic disorders, and fatty liver disease linked to metabolic syndrome. Not every person with these conditions develops cancer, but persistent inflammation, fibrosis, and repeated cycles of liver cell damage and repair are understood to increase the likelihood of malignant transformation over time. In some cases—particularly with hepatitis B—HCC can occur even without established cirrhosis.
HCC may present with few or nonspecific symptoms early on. When symptoms occur, they can include abdominal discomfort, unexplained weight loss, fatigue, jaundice, abdominal swelling, or worsening liver function in a person with known liver disease. Because early disease may be clinically silent, surveillance in higher-risk populations is a central concept in conventional hepatology. Outcomes vary widely depending on tumor stage, liver function, and overall health status; early detection is associated with substantially broader management options and better prognosis.
The topic is clinically important because HCC sits at the intersection of cancer care, hepatology, infectious disease, and metabolic health. It also illustrates the need for multidisciplinary care and careful interpretation of complementary approaches. Supportive therapies, symptom management, nutrition, quality of life, and liver health are areas where integrative discussions often arise, but these exist alongside the reality that HCC is a serious malignancy requiring specialist evaluation. Anyone with liver disease, new concerning symptoms, or questions about conventional and traditional approaches would generally need individualized guidance from qualified healthcare professionals.
Western Medicine Perspective
Western Medicine Perspective
In conventional medicine, hepatocellular carcinoma is understood as a malignancy that typically emerges in the setting of chronic hepatic inflammation, fibrosis, and cirrhosis. Diagnosis usually relies on a combination of clinical risk assessment, liver imaging, laboratory markers, and sometimes pathology. In at-risk patients, surveillance programs often use abdominal ultrasound with or without alpha-fetoprotein (AFP), though performance varies by patient factors and disease context. When a liver lesion is detected, multiphasic CT or MRI can often establish the diagnosis based on characteristic vascular patterns, reducing the need for biopsy in many cirrhotic patients.
Management is typically guided by tumor burden, vascular invasion, spread beyond the liver, underlying liver function, and performance status. Conventional approaches may include surgical resection, liver transplantation, local ablative procedures, transarterial therapies, radiation-based techniques in selected settings, and systemic therapy for advanced disease. Over the past decade, immunotherapy and targeted therapies have expanded treatment options, and multidisciplinary tumor boards are commonly used to tailor care. Research also emphasizes prevention through hepatitis B vaccination, antiviral treatment for hepatitis B and C, reduction of harmful alcohol use, and management of metabolic risk factors associated with fatty liver disease.
From an evidence standpoint, the strongest data in HCC relate to screening of high-risk groups, staging systems, imaging-based diagnosis, locoregional procedures, transplantation criteria, and systemic anticancer therapies. Conventional care also recognizes the importance of palliative and supportive care, including management of pain, ascites, nutrition concerns, and complications of cirrhosis. Because liver function can significantly affect treatment tolerance and outcomes, HCC care is often more complex than care for solid tumors arising in otherwise healthy organs.
Eastern & Traditional Perspective
Eastern/Traditional Medicine Perspective
In Traditional Chinese Medicine (TCM), liver cancer is not historically described in modern biomedical terms, but symptoms and patterns associated with abdominal masses, jaundice, pain, fatigue, digestive disturbance, and fluid accumulation are interpreted through pattern differentiation. Traditional frameworks may involve concepts such as Qi stagnation, blood stasis, damp-heat, toxin accumulation, phlegm, and deficiency of the liver, spleen, or kidney systems. TCM approaches have traditionally aimed to restore systemic balance, support digestion and vitality, reduce symptom burden, and improve quality of life rather than define cancer solely as a localized lesion.
In Ayurveda, serious liver disorders may be discussed through imbalances involving Pitta, disturbed digestion and metabolism, toxic accumulation, and depletion of tissue strength. Classical and contemporary Ayurvedic interpretations may focus on supporting agni (digestive/metabolic function), maintaining strength, and addressing patterns of inflammation, congestion, or fluid imbalance. In naturopathic and broader traditional frameworks, discussion often centers on constitutional support, nutrition, stress, symptom relief, and whole-person care.
Research on integrative and traditional approaches in HCC is heterogeneous and generally less definitive than the evidence base for conventional oncology. Some studies—particularly from East Asia—have examined Chinese herbal formulas, acupuncture, and integrative supportive care alongside standard treatment, with interest in symptom relief, treatment tolerance, immune modulation, and quality-of-life outcomes. However, study quality varies, formulations are not standardized across traditions, and herb-drug interactions, liver toxicity, and effects on coagulation are important concerns in people with cancer and impaired liver function. For these reasons, traditional approaches are generally discussed as complementary frameworks that require careful coordination with oncology and hepatology teams rather than as substitutes for evidence-based cancer care.
Related Topics
Hepatitis B
Hepatitis B — a condition in the health ontology.
How They Relate
Hepatitis B & Liver Cancer (Hepatocellular Carcinoma)
Hepatitis B virus (HBV) infection is one of the most important causes of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The link is both biological and epidemiologica...
Evidence & Sources
Promising research with growing clinical support from multiple studies
- World Health Organization (WHO), Cancer Fact Sheets
- National Cancer Institute (NCI), Hepatocellular Carcinoma resources
- American Association for the Study of Liver Diseases (AASLD) Practice Guidance
- European Association for the Study of the Liver (EASL) Clinical Practice Guidelines
- The Lancet
- CA: A Cancer Journal for Clinicians
- Journal of Hepatology
- Hepatology
- National Center for Complementary and Integrative Health (NCCIH)
- BMC Complementary Medicine and Therapies
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.